News Medical

Signal transduction via the EGFR pathway likely to be involved in lenvatinib resistance

The multitargeted tyrosine kinase inhibitor (MKI), lenvatinib, is widely used to treat advanced and metastatic thyroid cancer. However, the molecular mechanisms by which thyroid cancer cells become ...
ascopubs.org

RNA sequencing to characterize pathways in EGFR-mutated non-small cell lung cancer.

Prognostic value of baseline immune suppressive biomarkers to select non-small cell lung cancer (NSCLC) patients (pts) likely to benefit from the plinabulin/docetaxel (Plin/Doc) combination. This is ...
The American Journal of Managed Care

Roy Beveridge, MD, Discusses Pathways, NCCN Guidelines in EGFR Exon 20 Insertion+ NSCLC

Beveridge, now with Avalere Health, addressed the importance of clinical pathways in selecting therapies in non-small cell lung cancer (NSCLC) and the emergence of options for EGFR Exon 20 Insertion+ ...
ascopubs.org

Survey of actionable driver mutations KRAS and EGFR in non–small cell lung cancer to evaluate coexisting splicing gene and pathway mutations: A CBioportal database analysis.

Five-year outcomes with first-line (1L) nivolumab + ipilimumab + chemotherapy (N + I + C) vs C in patients (pts) with metastatic NSCLC (mNSCLC) in CheckMate 9LA. Co-occurring RNA splicing alterations ...
The American Journal of Managed Care

Edward Arrowsmith, MD, MPH, Discusses EGFR Exon 20 Insertion+ NSCLC, How Knowledge Fits Into Pathways

Edward Arrowsmith, MD, MPH, medical director for clinical pathways for OneOncology, discussed treatment challenges in EGFR Exon 20 insertion+ non-small cell lung cancer (NSCLC) and best practices in ...
The New England Journal of Medicine

New Creatinine- and Cystatin C–Based Equations to Estimate GFR without Race

Current equations for estimated glomerular filtration rate (eGFR) that use serum creatinine or cystatin C incorporate age, sex, and race to estimate measured GFR. However, race in eGFR equations is a ...